Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etrapopa is a small molecule drug developed as a thrombopoietin receptor agonist (TPORA) for the treatment of immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). It is formulated as an oral dry suspension, specifically the ethanolamine salt form. Etrapopa acts by stimulating the thrombopoietin receptor to promote platelet production in patients with chronic or persistent ITP and SAA. The drug has been submitted for registration in China and is under priority review for these indications. Clinical studies have shown that it improves platelet counts and cellular immune function in patients with refractory primary ITP when used alone or in combination with other agents[5][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etrapopa.